Table 7 The impact of clinicopathologic parameters on prognosis by univariate analysis
From: Metabolic phenotypes in primary unknown metastatic carcinoma
| Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | ||
|---|---|---|---|---|
| No. of cases | Patient death | Median survival (95% CI) (months) | P -value | |
| Age | 0.326 | |||
| <50 | 20 | 5 | 96 (70–123) | |
| ≥50 | 39 | 13 | 43 (30–56) | |
| Sex | 0.539 | |||
| Male | 35 | 10 | 88 (65–110) | |
| Female | 24 | 8 | 74 (44–103) | |
| Histologic subtype | 0.002 | |||
| AD | 21 | 11 | 23 (10–36) | |
| PD | 13 | 1 | 34 (28–40) | |
| SQ | 17 | 5 | 49 (33–65) | |
| UD | 8 | 1 | 115 (86–145) | |
| Clinical subtype | <0.001 | |||
| Nodal type | 25 | 3 | 107 (88–126) | |
| Single organ type | 10 | 1 | 119 (95–143) | |
| Intermediate type | 10 | 4 | 21 (9–32) | |
| Carcinomatosis type | 14 | 10 | 6 (3–10) | |
| Organs involved | 0.701 | |||
| Lymph node | 38 | 12 | 77 (55–99) | |
| Bone | 6 | 2 | 40 (18–62) | |
| Brain | 7 | 1 | 31 (23–39) | |
| Other | 8 | 3 | 83 (40–126) | |
| Postoperative treatment | 0.638 | |||
| None | 7 | 1 | 107 (75–139) | |
| Chemotherapy | 20 | 7 | 77 (45–108) | |
| Radiation therapy | 15 | 4 | 52 (36–68) | |
| Chemo-radiation therapy | 17 | 6 | 25 (18–33) | |